The award, presented annually to a company that has demonstrated excellence in implementing strategies that proactively create value through research and development activities, with a focus on improving the return on the investment that customers make in its products, recognizes the achievements in BioCell Technology’s diligence and innovation of the BioCell Collagen II ingredient.
"BioCell Technology has proven consistently to be a significant contender in a market that has been dominated by glucosamine/chondroitin products," said Suhail Ishaq, Vice President of BioCell Technology. "We appreciate Frost & Sullivan’s recognition of our efforts to deliver solution driven values to our customers and we are deeply honored to have received this award. "
“Significant competition in the market for Collagen peptides means that manufacturers have to distinguish themselves with optimum technical and business support to become market leaders,” said Dr. Kaushik Ramakrishnan, Senior Research Analyst at Frost & Sullivan. “BioCell Technology has the right combination of supporting clinical data and a Co-Branding strategy. This is augmented by their strong IP protection, which ensures a long term and delightful relationship with clients and consumers.”
The patented ingredient, known as Biocell Collagen II, comes from articular cartilage. The three main constituents, collagen type II, chondroitin sulfate, and hyaluronic acid, are reduced to highly-bioavailable, very low molecular weight forms through a hydrolysis process.
This matrix is said to be similar to that in human articular cartilage, and the ingredient is used in value-added products to promote healthy joints and youthful-looking skin.
The ingredient received generally recognised as safe (GRAS) status from an independent panel in October 2010 following assessment on safety and toxicology and also good manufacturing practices (GMPs).